Kappa Opioid Aggregates in Trehalose Matrices for Oral Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Kappa opioid receptor agonists face challenges in achieving efficient oral delivery and maintaining bioavailability due to their unique physicochemical properties, leading to instability and unpredictable long-term stability in pharmaceutical formulations.
Innovation Solution
A formulation combining a kappa opioid receptor agonist with medium chain fatty acids or their salts and glycerides as absorption enhancers, embedded in oligomeric saccharides like trehalose, to optimize uptake and stability for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If kappa opioid receptor agonists are formulated for oral delivery, then bioavailability can be improved, but long-term stability deteriorates due to component interactions
Solution Approach 1:
The patent introduces medium chain fatty acids and their glycerides as intermediary substances that mediate between the kappa opioid receptor agonist and the gastrointestinal environment. These intermediaries enhance absorption through the gastrointestinal tract while the oligomeric saccharide matrix acts as a stabilizing intermediary that prevents direct interactions between formulation components, thereby resolving the contradiction between improved bioavailability and maintained long-term stability.
2Reliability
If absorption enhancers are added to improve uptake, then biological activity is enhanced, but formulation complexity increases
Solution Approach 1:
The patent combines multiple functional components into a unified formulation system where medium chain fatty acids, their glycerides, and oligomeric saccharides work synergistically. The absorption enhancers (fatty acids and glycerides) are merged with the stabilizing matrix (oligomeric saccharides) to create a single integrated formulation that simultaneously achieves enhanced biological activity through improved absorption while maintaining stability, thereby managing formulation complexity through functional integration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation enhances the bioavailability and stability of kappa opioid receptor agonists, ensuring effective prophylaxis or treatment of associated diseases with improved long-term stability and biological activity.
Implementation Method 1
a medium chain fatty acid or a salt of a medium chain fatty acid, and a medium chain fatty acid glyceride as absorption enhancers suitable for optimizing uptake of the kappa opioid receptor agonist from the gastrointestinal system
Implementation Method 2
a biologically active peptide embedded in an oligomeric saccharide forming a particle including the stabilized biologically active peptide
Data Source
AI summary
The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist and an absorption enhancer, the absorption enhancer includes a medium chain fatty acid or a salt of a medium chain fatty acid; and a medium chain fatty acid glyceride. The kappa opioid receptor agonist may be embedded in an oligosaccharide, such as trehalose. Also provided are capsules containing the oral formulations of the kappa opioid receptor agonists and the absorption enhancer of the invention and methods use of these formulations for the prophylaxis and treatment of variety of kappa opioid receptor-associated diseases and conditions such as pain, pruritus and inflammation; the method comprising administering to the mammal the formulation comprising the kappa opioid receptor agonist and an absorption enhancer.